An epidemiologic-based survey of public attitudes towards predictive genetic testing in Russia

Personalized Medicine

Volumn 7, Issue 3, 2010, Pages 291-300

  Makeeva, Oksana A ^a,b   Markova, Valentina V ^a   Roses, Allen D ^c,d   Puzyrev, Valery P ^a  

^a RESEARCH INSTITUTE OF MEDICAL GENETICS   (Russian Federation)

^b RESEARCH INSTITUTE FOR COMPLEX ISSUES OF CARDIOVASCULAR DISEASES   (Russian Federation)

^c Deane Drug Discovery Institute Durham   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

Common diseases; Direct to consumer genetic service; Genetic discrimination; Genetic risk assessment; Genetic testing; Predictive diagnostics; Preventable health condition; Public attitude

Indexed keywords

APOLIPOPROTEIN E;

ATTITUDE; DECISION MAKING; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; EDUCATIONAL STATUS; GENETIC COUNSELING; GENETIC RISK; GENETIC TEST; GENOME; HEALTH STATUS; HEALTH SURVEY; HUMAN; INCOME; LIFESTYLE MODIFICATION; PREDICTION; PRIORITY JOURNAL; PUBLIC ATTITUDE; REVIEW; RISK ASSESSMENT; RUSSIAN FEDERATION; SELF EVALUATION; VALIDATION PROCESS;

EID: 77951832128     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.23     Document Type: Review

References (44)

1. Haga SB, Khoury MJ, Burke W: Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nat. Genet. 34, 347-350 (2003). (Pubitemid 36935322)
2. McGuire AL, Burke W: An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA 300, 2669-2671 (2008).
3. Grosse SD, Khoury MJ: What is the clinical utility of genetic testing? Genet. Med. 8, 448-450 (2006). (Pubitemid 44289007)
4. Offit K: Genomic profiles for disease risk: predictive or premature? JAMA 299, 1353-1355 (2008). (Pubitemid 351439082)
5. Borry P, Evers-Kiebooms G, Cornel MC, Clarke A, Dierickx K: Genetic testing in asymptomatic minors. Eur. J. Hum. Genet. 17, 711-719 (2009).
6. Gurwitz D, Bregman-Eschet Y: Personal genomics services: whose genomes? Eur. J. Hum. Genet. 17, 883-889 (2009).
7. Evans JP, Green RC: Direct to consumer genetic testing: avoiding a culture war. Genet. Med. 11, 568-569 (2009).
8. Ng PC, Murray SS, Levy S, Venter JC: An agenda for personalized medicine. Nature 461, 724-726 (2009).
9. Compares the results of two direct-to-consumer companies on risk assessments for 13 diseases in five individuals, and proposes several recommendations based on their findings for both direct-to-consumer companies and the scientific community on how to improve genetic diagnostics.
10. Khoury MJ, McBride CM, Schully SD et al.: The scientific foundation for personal genomics: recommendations from a national Institutes of Health Centers for Disease Control and Prevention multidisciplinary workshop. Genet. Med. 11 (8), 559-567 (2009).
11. Sanderson SC, Wardle J, Jarvis MJ, Humphries SE: Public interest in genetic testing for susceptibility to heart disease and cancer: a population-based survey in the UK. Prevent. Med. 39 (3), 458-464 (2004). (Pubitemid 39093900)
12. Berth H, Balck F, Dinkel A: Attitudes toward genetic testing in patients at risk for HNPCC/FAP and the German population. Genet. Test. 6, 273-280 (2002). (Pubitemid 36020051)
13. Aro AR, Hakonen A, Hietala M et al.: Acceptance of genetic testing in a general population: age, education and gender differences. Patient Educ. Couns. 32, 41-49 (1997). (Pubitemid 27395978)
14. Henneman L, Timmermans DRM, Van Der Wal G: Public attitudes toward genetic testing: perceived benefits and objections. Gen. Testing. 10 (2), 139-145 (2006). (Pubitemid 43993300)
15. Jallinoja P, Aro AR: Does knowledge make a difference? The association between knowledge about genes and attitudes toward gene tests. J. Health Comm. 5, 29-39 (2000).
16. Wilde A, Meiser B, Mitchell PB, Schofield PR: Public interest in predictive genetic testing, including direct-to-consumer testing, for susceptibility to major depression: preliminary findings. Eur. J. Hum. Genet. 18, 47-51 (2010).
17. Gollust SE, Hull SC, Wilfond BS: Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA 288, 1762-1767 (2002).
18. Brunger JW, Murray GS, O'Riordan M, Matthews AL, Smith RJ, Robin NH: Parental attitudes toward genetic testing for pediatric deafness. Am. J. Hum. Genet. 67, 1621-1625 (2000).
19. Umans-Eckenhausen MA, Oort FJ, Ferenschild KC, Defesche JC, Kastelein JJ, de Haes JC: Parental attitude towards genetic testing for familial hypercholesterolaemia in children. J. Med. Genet. 39 (9), E49 (2002).
20. Elwood JM: Public health aspects of breast cancer gene testing in Canada. Part 2: selection for and effects of testing. Chronic. Dis. Can. 20 (1), 14-20 (1999).
21. Neumann PJ, Hammitt JK, Mueller C et al.: Public attitudes about genetic testing for Alzheimer's disease. Health Aff. (Millwood) 20 (5), 252-264 (2001). (Pubitemid 33710358)
22. Examines the interest in a hypothetical predictive test for Alzheimer's disease in the general population.
23. Makeeva OA, Markova V V, Puzyrev VP: Public interest and expectations concerning commercial genotyping and genetic risk assessment. Pers. Med. 6 (3), 329-341 (2009).
24. Earlier paper published on the survey's results of the Russian general public's attitude towards different aspects of predisposition genetic testing.
25. Stewart-Knox BJ, Bunting BP, Gilpin S et al.: Attitudes toward genetic testing and personalized nutrition in a representative sample of European consumers. Br. J. Nutr. 101, 982-989 (2008).
26. Meiser B, Kasparian NA, Mitchell PB et al.: Attitudes to genetic testing in families with multiple cases of bipolar disorder. Genet. Test. 12 (2), 233-243 (2008). (Pubitemid 351860443)
27. Lerman C, Biesecker B, Benkendorf JL et al.: Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J. Natl. Cancer. Inst. 89, 148-157 (1997). (Pubitemid 27034791)
28. Bernhardt C, Schwan AM, Kraus P, Epplen JT, Kunstmann E: Decreasing uptake of predictive testing for Huntington's disease in a German centre: 12 years' experience (1993-2004). Eur. J. Hum. Genet. 17 (3), 295-300 (2009).
29. Creighton S, Almqvist EW, MacGregor D et al.: Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clin. Genet. 63 (6), 462-475. (2003). (Pubitemid 36944091)
30. Toiviainen H, Jallinoja P, Aro AR, Hemminki E: Medical and lay attitudes towards genetic screening and testing in Finland. Eur. J. Hum. Genet. 11, 565-572 (2003). (Pubitemid 37038770)
31. Press NA, Yasui Y, Reynolds S, Durfy SJ, Burke W: Women's interest in genetic testing for breast cancer susceptibility may be based on unrealistic expectations. Am. J. Med. Genet. 99 (2), 99-110 (2001). (Pubitemid 32204778)
32. McBride CM, Alford SH, Reid RJ, Larson EB, Baxevanis AD, Brody LC: Characteristics of users of online personalized genomic risk assessments: implications for physician-patient interactions. Genet. Med. 11 (8), 582-587 (2009).
33. Presents results of a population-based study that prospectively evaluated effects of offering genetic testing for multiple health conditions to a large and heterogeneous population of healthy people.
34. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS: A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet. Med. 10, 19-32 (2008).
35. Ulrich CM, Kristal AR, White E, Hunt JR, Durfy SJ, Potter JD: Genetic testing for cancer risk: a population survey on attitudes and intention. Comm. Genet. 1, 213-222 (1998).
36. Wilhelm K, Meiser B, Mitchell PB et al.: Issues concerning feedback about genetic testing and risk of depression. Br. J. Psychiatry. 194 (5), 404-410 (2009).
37. Nelson HD, Huffman LH, Fu R, Harris EL: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U. S. Preventive services task force. Ann. Intern. Med. 143, 362-379 (2005). (Pubitemid 41266609)
38. Green RC, Roberts JS, Cupples LA et al.: Disclose of APOE genotype for risk of Alzheimer's Disease. N. Engl. J. Med. 361 (3), 245-254 (2009).
39. Results of a prospective study that examined the effect of APOE genotype disclosed to the adult progeny of patients with Alzheimer's disease.
40. Mayeux R, Saunders AM, Shea S et al.: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N. Engl. J. Med. 338 (8), 506-511 (1998).
41. Post SG, Whitehouse PJ, Binstock RH et al.: The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA 277 (10), 832-836 (1997). (Pubitemid 27111321)
42. Lutz MW, Crenshaw D, Saunders AM, Roses AD: Structural variants and risk for complex disease: Alzheimer's disease as a model for autosomal codominant traits. Alzheimer's Dementia 6, 125-113 (2010).
43. Roses AD, Lutz MW, Amrine-Madsen H et al.: A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 22, 1-10 (2009).
44. Caulfeld T, Ries NM, Ray PN, Shuman C, Wilson B: Direct-to-consumer genetic testing: good, bad or benign? Clin. Genet. 77 (2), 101-105 (2010).